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Typhoid fever, caused by Salmonella enterica serovar Typhi is a severe world health problem, and current 
vaccines are quite defective. In this work a completely new vaccine is proposed, based on the immunologic 
properties of Lactic Acid Bacteria. This vaccine is designed with the necessities of the population affected by 
the disease, including safety, economically viable production and biological containment system. 
Recombinant bacteria as vaccine vector have been 
studied since the early 1980’. Including pathogenic and non-pathogenic 
bacteria expressing heterologous antigens. Because of the hazard of 
reversion to a virulent state, non-pathogenic bacteria are a better candidate 
to treat typhoid, where children are the most affected subpopulation. 
 
 
 
 
 
 
 
 
 
 
 
 
ü Mucosal administration. They can elicit an immune 
response through the natural route of infection of the pathogen. In 
addition, this avoids the use of needles and medically trained personal 
for its administration. 
ü Inexpensive production. As the bacteria are administered 
whole and alive, the downstream process in its production is much 
simpler than in other vaccines. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
High (>100 cases per 100.000 people per year). 
Medium (10-100 cases per 100.000 per year). 
Low (<10 cases per 100.000 per year). 
Figure 1. Incidence of typhoid  fever. Data extracted from Crump et al. 2004 (1). 
1. The Disease 
Typhoid fever is still a serious problem 
worldwide. Even though it’s controlled in first world countries:, 
216.000 deaths and 22 million cases are estimated per year (1). 
Cases of typhoid fever are more frequent in children and infants. 
 
The host response is complex. To control de 
bacteria, it requires a  T-cell response but also the production of 
antibodies (even though it’s an intracellular pathogen). 
The two licensed vaccines are 
very defective. Meanwhile the attenuated 
strain Ty21a vacinne is not available for children 
under 6 years old, the capsular Vi polysaccharide 
vaccine elicits poor response in infants. Both 
vaccine have a poor rate of protection and require 
periodical re-vaccination. 
 
 
Flagellin is a target of innate 
and adaptative immunity. This 
protein is recognized by innate immunity 
(throughTLR-5). It’s also pointed to be 
recognized by T-cell and antibodies against 
flagellin are believed to be protective. 
However, Salmonella has a flagellar phase 
variation between the two distinct flagellins 
FliC and FljB. Thus, Salmonella flagellins can 
be protective, but both flagellins must be 
present in the vaccination. 
 
Salmonella Typhimurium is 
the murine model. Salmonella 
enteriva serovar Typhi is the causative agent 
of typhoid fever but only infects humans. S. 
enterica serovar Typhimurium is the 
laboratory model in murine infection. 
 
2. Lactococcus lactis 3. The vaccine 
Figure 3. Lactococcus lactis. Photography: 
Bart Weimer, Utah State University 
1. Plasmid Construction  
2. Bacteria recombination 
4. Animal immunization 
3. In vitro analysis 
6. Prophylactic analysis 
5. In vivo analysis 
Figure 5. a) Example of the plasmid constructed with Signal 
peptide from USP145 protein. b) Map of the plasmids proposed 
to clone the antigene genes. Green line represents sequence 
from L. lactis. Flagellin genes from S. Typhimurium will be 
cloned through OE-PCR  and inserted in pGhost5 (3). 
Variables: Signal peptide, promotor 
The resultant plasmid will be 
transformed into L. lactis. 
The integration will be forced 
through temperature 
restriction of replication and 
selection. The excision will 
be improved through plasmid 
replication. 
Confirmation 
As the immune response is hard to predict, immunization must be 
empirically found.  
Variables: ammount (CFU/mice) and frequency of 
dose, route (oral/intranasally). 
 
• Protein synthesis. 
• Enough bacterial growth. 
• Biological containment. 
Quantification 
• Antibodies (serum and 
mucosa) 
• Cytokines (from ex vivo 
splenocytes and lymphocytes) 
Lethal challenge: 
(with virulent  
Salmonella Typhimurium) 
• Monitorization of mortality 
• Organ examination.
The immune response is 
hard to predict. The main 
drawback of Lactic acid bacteria vaccines 
is the dependence of many variables in 
the immune response elicited. This 
includes: strain, subcellular location of 
the antigen, the antigen itself, the animal 
model, and the route and regime of 
vaccination. 
Figure 2. Salmonella typhiPhotography: J.P. 
Duguid and J.F. Wilkinson 
A biological containment 
system is needed using a 
genetically modified organism as vaccine 
vector. Thymidylate synthase gene (thyA) 
deletion is a bactericidal auxotrophy, so 
the generated strain requires a thymine or 
thymidine supplementation to survive. 
The gene substitution proposed is based 
on the work of Biswas et al. (3). 
Bibliography: 
1. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World 
Health Organ. 2004;82(5):346-353.  
2. Bahey-El-Din M, Gahan CGM, Griffin BT. Lactococcus lactis as a cell factory 
for delivery of therapeutic proteins. Current Gene Therapy. 2010;10(1):34-
45.  
3. Biswas I, Gruss A, Ehrlich SD, Maguin E. High-efficiency gene inactivation and 
replacement system for gram-positive bacteria. J Bacteriol. 
1993;175(11):3628-3635.  
4. Steidler L, Neirynck S, Huyghebaert N, et al. Biological containment of 
genetically modified lactococcus lactis for intestinal delivery of human 
interleukin 10. Nat Biotechnol. 2003;21(7):785-789.  
Figure 4. Growth of wildype L. lactis 
strain and thyA- strain in different 
media. Data from Biswas et al. (4). 
Introduction 
Lactic acid bacteria and 
Lactococcus lactis have 
been studied as vaccine vectors for 
long and there have been several 
protection trials in animal models (2). 
Their  benefits are: 
ü Safety. They have been used
for thousands of years in dairy 
food production and they are 
generally recognized as safe 
(GRAS). 
The Benefits of this vaccine 
Unsatisfactory? 
Unsatisfactory? 
Safety Economical 
Oral Effective? 
